American Academy of Allergy, Asthma & Immunology - Dermatology

Jolanta Bernatoniene, PhD, discussed positive results from the APeX-P study of oral berotralstat in children with hereditary angioedema.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress.

Bernstein also discussed other unmet needs in the field and how his center is working to address them.

Eapen discussed her research into analyzing the cord blood methylome for markers that predict atopic dermatitis risk at the AAAAI/WAO Joint Congress.

Casale discussed data from the phase 3 LIBERTY-CSU CUPID studies evaluating dupilumab’s use in urticaria.

Greiwe discussed findings from the phase 3 ADORING 1 and 2 trials in people as young as 2 years of age.

Casale discussed data from the phase 1b/2a BEACON study he presented at the AAAAI/WAO Joint Congress.

Metz shared highlights from 2 presentations he gave on barzolvolimab’s efficacy at the AAAAI/WAO Joint Congress.

Alexis discussed the latest research in the field and new management strategies for children with atopic dermatitis.

Chovatiya discussed his talk at the 2025 AAAAI/WAO Joint Congress.

Participants in a phase 3 OLE had a mean monthly attack rate of 0.08.

Sebetralstat has a PDUFA date of June 12, 2025, for treating HAE in patients 12 years and older.

Ahead of AAAAI 2025, HCPLive spoke with Jaroenpuntaruk about varying hypersensitivity reactions in patients with atopic diseases on biologics.

These phase 3 findings from the INTEGUMENT-PED clinical trial highlight the efficacy and safety of roflumilast cream 0.05% for pediatric patients with atopic dermatitis.

A study analyzed hypersensitivity reactions to biologics for atopic diseases, highlighting reaction types, severity, and biologic discontinuation rates.

In new data to be presented at AAAAI, the therapy was well-tolerated in people as young as 2 years old.

By week 52, remibrutinib and placebo-to-remibrutinib groups had similar levels of urticaria control.

Data from 3 pooled phase 3 studies in children, adolescents, and adults will be presented at the AAAI/WAO Joint Congress.

A study found many patients with chronic spontaneous urticaria need add-on or higher-dose therapies, revealing gaps in treatment. Findings will be presented at AAAAI 2025.

At week 12, a higher proportion of participants on rilzabrutinib 1200mg a day (60.9%) achieved AAS7 scores of 0 than placebo-treated participants (30.8%).

Infants who develop atopic dermatitis show early cheek skin barrier dysfunction with delayed FLG processing, low ceramides, and high IL-18. The study will be presented at AAAAI 2025.

At 6 months, baseline monthly rates of 0.45 for mild, 1.54 for moderate, and 0.14 for severe attacks were reduced to 0.10, 0.08, and 0.00, respectively.

Bernstein discussed recent and upcoming research and management of angioedema in patients with urticaria.

Children with severe atopic dermatitis saw > 5 percentile height gains after 16 weeks of dupilumab, per a study to be presented at AAAAI 2025.

Around half of participants had insufficient vitamin D levels.

A study found the Skin Barrier Meter accurately measures skin barrier function in children with atopic dermatitis, offering a fast, non-invasive assessment within 5 seconds.

Fifteen of 16 patients with chronic ulcers in a small study had positive patch test to common wound care products.

A study found distinct DNA methylation patterns at birth linked to early-onset atopic dermatitis by age 2. Findings will be presented at AAAAI 2025.

These findings were from a 52-week analysis of a Phase-2 trial in participants with chronic spontaneous urticaria.

Avapritinib 25mg daily significantly improved quality of life (QoL), disease control, and basal serum tryptase (BST) levels.